Redhill Biopharma Long Term Debt

Redhill Biopharma (RDHL) currently reports a long-term debt of $900K as of December 2025. That compares with $3K in the prior-year period — up 29900.0% year over year. Use the charts on this page to explore Redhill Biopharma's long-term debt history and peer comparisons.

Redhill Biopharma's long-term debt increased from $3K to $900K — a 29900.0% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Redhill Biopharma reported $900K in long-term debt as of December 2025. That compares with $3K in the prior-year period — up 29900.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $900K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Redhill Biopharma, and consider following RDHL for alerts when major investors trade the stock.

Redhill Biopharma is classified in the Healthcare sector. On long-term debt, it currently shows $900K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RDHL with unrelated industries.